Renata Martin
VP & Head of Gene Therapy

Renata leads the gene therapy program at Replay, where she serves as VP of R&D and Head of Gene Therapy. She brings expertise in viral vector engineering, CRISPR-based genome editing, and cell therapy development, and has advanced a preclinical HSV-based gene therapy program for Dystrophic Epidermolysis Bullosa from vector design through pre-IND. Prior to Replay, Dr. Martin worked in cell line engineering for AAV manufacturing at Resilience. Before Resilience, she was part of the Gene Engineering group at Poseida Therapeutics, contributing to CAR-T cell engineering and iPSC-based cell therapy programs. Dr. Martin received her PhD from Stanford University School of Medicine in the Department of Stem Cell and Regenerative Medicine, where her research on genome editing and pluripotent stem cell safety was published in Cell Stem Cell and Nature Communications. She holds a BS in Immunology from Brown University and is an inventor on several patents in gene and cell therapy.